Aavnergene Inc

AAVnerGene is a leading Biotech company specializing in advanced gene therapy technologies using the AAV platform. Found in Rockville, Maryland, our state-of-the-art facility spans over square feet, is dedicated to developing innovative gene therapy solutions. With 20+ years of AAV gene therapy expertise, our leadership team has contributed to a multitude of groundbreaking publications and patented technologies. We support gene therapy from early R&D to preclinical, offering integrated solutions, including vector design, packaging, capsid library construction, and screening with our key technologies: AAVone, AAVdual, and AAVtri: 3 proprietary systems that enhance AAV production efficiency. ATHENA platform: A cutting-edge suite (ATHENA I, II, and revolutionizing AAV capsid selection and development. AAV-Q Platform for AAV potency(AAV-TCID50) and rcAAV analysis Our Mission: Revolutionize gene therapy by overcoming key challenges in AAV technology and accelerating the development of safe, effective, accessible, and affordable therapies to patients worldwide. Our Vision: To become a global leader in gene therapy by empowering researchers with cutting-edge AAV technologies that drive innovation and transform patient outcomes. Our Commitment: Quality and safety Customer First Our Values: Excellence Accountability InnovationTeamwork: Partner with AAVnerGene to tap into advanced technologies and personalized support. Together, we can help move gene therapy innovations forward.